摘要
目的:评估聚乙二醇干扰素α-2a联合利巴韦林抗病毒治疗前后慢性丙型肝炎肝脏的病理变化。方法:选取我院2014年10月至2015年10月收治的40例慢性丙肝患者为研究对象,随机将患者分为观察组与对照组,每组20例。观察组采用聚乙二醇干扰素α-2a联合利巴韦林(PR方案)抗病毒治疗,对照组采用一般保肝降酶治疗,比较两组患者治疗前后谷丙转氨酶(ALT)、丙型肝炎病毒(HCV)RNA水平及肝脏病理组织的变化。结果:治疗后,观察组ALT复常率80%,与对照组比较无统计学差异(P>0.05);观察组HCVRNA转阴率为90.0%,与对照组比较显著升高(P<0.05);观察组肝组织炎症活动度、纤维化程度较治疗前明显降低,且显著低于对照组(P<0.05)。结论:抗病毒治疗能明显降低肝脏炎症活动度及纤维化程度;从病理的角度评估抗病毒治疗的效果有着重要的意义。
Objective： To observe the pathological changes of chronic hepatitis C after the treatment of peg-interferon α-2a combined with ribavirin. Methods： 40 patients with chronic hepatitis C visited our hospital from October 2014 to October 2015 as the research object,were randomly divided into two groups,20 cases in each group. Observation group was treated with peg interferon α-2a and ribavirin,the control group was given general hepatoprotective treatment,The levels of ALT,HCVRNA and the pathological tissue of the two groups were compared. Results： After treatment,the observation group ALT recovery rate was 80%,there’s no significant difference with the control group（ P 〉0.05）; the observation group HCVRNA negative rate was90%,compared with the control group were significantly higher（ P 〈0.05）; liver inflammation and fibrosis of the observation group was significantly lower than before,and significantly lower than the control group（ P 〈0.05）. Conclusion： Antiviral treatment can significantly reduce the degree of liver inflammatory activity and fibrosis.It is of great significance to evaluate the effect of antiviral therapy from the pathological point.
出处
《河北医学》
CAS
2017年第3期356-359,共4页
Hebei Medicine
基金
广东省佛山市医学类科技攻关项目
(编号:2014AB000262)
